WO2016041438A1 - 一种柚皮苷与盐酸非索非那丁药物组合物及其制剂 - Google Patents

一种柚皮苷与盐酸非索非那丁药物组合物及其制剂 Download PDF

Info

Publication number
WO2016041438A1
WO2016041438A1 PCT/CN2015/088433 CN2015088433W WO2016041438A1 WO 2016041438 A1 WO2016041438 A1 WO 2016041438A1 CN 2015088433 W CN2015088433 W CN 2015088433W WO 2016041438 A1 WO2016041438 A1 WO 2016041438A1
Authority
WO
WIPO (PCT)
Prior art keywords
naringin
pharmaceutical composition
group
fexofenadine hydrochloride
hydrochloride
Prior art date
Application number
PCT/CN2015/088433
Other languages
English (en)
French (fr)
Inventor
苏薇薇
焦豪妍
廖彦
李沛波
彭维
王永刚
Original Assignee
中山大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 中山大学 filed Critical 中山大学
Publication of WO2016041438A1 publication Critical patent/WO2016041438A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin

Definitions

  • the present invention relates to a naringin pharmaceutical composition for use in relieving cough, phlegm and asthma, and a preparation thereof.
  • Cough and sputum are two common symptoms of respiratory diseases. They are closely related in pathology. Generally, coughing is more common, and phlegm is often coughing. Long-term unhealed may cause emphysema, bronchiectasis, and pulmonary heart disease. Cough variant asthma refers to a special type of asthma with chronic cough as the main or only clinical manifestation.
  • the most widely used antitussive drugs in pharmaceutical medicines include codeine phosphate and dextromethorphan hydrobromide.
  • Codeine phosphate is a central nervous system chemical widely used for coughing or catching cold.
  • Common adverse reactions are: psychopathy or fantasy; weak, slow or irregular breathing; heart rate is fast or slow, abnormal.
  • Uncommon adverse reactions convulsions, tinnitus, tremors, or uncontrolled muscle movements; urticaria; allergic reactions such as rash, rash, or swollen face; mental depression and muscle rigidity. Long-term applications can cause dependence. The tendency of the usual dose to cause dependence is weaker than other morphine drugs.
  • Typical symptoms are: goose bumps, loss of appetite, diarrhea, toothache, nausea and vomiting, runny nose, chills, sneezing, yawning, sleep disorders, stomach cramps, excessive sweating, weakness, heart rate, emotional agitation or unexplained causes Fever.
  • Dextromethorphan hydrobromide is also a commonly used central nervous chemical cough suppressant, which consumers can buy at pharmacies.
  • serious adverse reactions have occurred, especially the abuse.
  • the foreign patients have repeatedly reported the capsules packed with powdered dextromethorphan. Cause death.
  • the US Food and Drug Administration is constantly concerned about the abuse of dextromethorphan and issued a warning not to abuse dextromethorphan.
  • the US Food and Drug Administration says that the correct use of dextromethorphan in small doses can safely and effectively suppress cold symptoms, but abuse can cause death and other serious adverse effects such as brain damage, seizures, loss of consciousness and irregular heartbeat.
  • Naringin has a good antitussive, expectorant and antiasthmatic effect, and has no addiction and minimal side effects. Therefore, the development of a more effective naringin compound preparation is a good way to develop the clinical application of naringin.
  • the present invention provides a naringin pharmaceutical composition for cough, expectorant and asthma, and a preparation thereof.
  • the daily dosage is recommended to be naringin content of 27.5 to 275 mg and the content of fexofenadine hydrochloride to be 30 to 300 mg.
  • the preferred dosage is 40 mg of naringin and 40 mg of fexofenadine hydrochloride per unit of preparation (formulation).
  • test data of the pharmaceutical preparations prepared by the two pharmaceutical compositions of the present invention show that the combination of naringin and fexofenadine hydrochloride has synergistic effect according to the ratio of the present invention, and the compound effect is obviously superior to the single component, and better. Played a role in relieving cough, phlegm and asthma.
  • the pharmaceutical composition according to the present invention can treat wheezing caused by cough, expectoration and cough variant asthma, and does not cause side effects of lethargy, lethargy, nausea and vomiting when taken, and the pharmaceutical composition can be added to conventional excipients. According to any conventional method, a drug for cough, expectorant and asthma is prepared.
  • Example 1 Inhibition of guinea pig cough caused by niacin
  • naringin is prepared according to the daily dosage of 120mg
  • fexofenadine hydrochloride is prepared according to the daily dosage of 60mg
  • composition (1) is based on daily dosage of naringin 27.5mg
  • hydrochloric acid Formulation (2) was prepared according to human daily dosage of naringin 27.5mg and desofindine hydrochloride 300mg
  • composition (3) group was 275mg of naringin and fenoflavin hydrochloride.
  • composition (4) group according to human daily dosage of naringin 275mg, desofindine hydrochloride 300mg; composition (5) group according to daily dosage of naringin 120mg, fexofenadine hydrochloride Formulated in 120 mg.
  • Instrument YLS-8A induces cough and asthma (Shandong Medical Science Equipment Station products).
  • mice Male and female, weighing 30-40g, were provided by Guangdong Medical Laboratory Animal Center.
  • naringin is prepared according to the daily dosage of 120mg
  • non-sonotepine hydrochloride is prepared according to the daily dosage of 120mg
  • composition (3) group was 275mg of naringin and fenoflavin hydrochloride.
  • composition (4) group according to human daily dosage of naringin 275mg, desofindine hydrochloride 300mg; composition (5) group according to daily dosage of naringin 120mg, fexofenadine hydrochloride Formulated in 120 mg.
  • Kunming mice male and female, were randomly divided into blank control group, ambroxol group, naringin group, fexofenadine hydrochloride, composition (1) ⁇ composition (5) group, 10 groups in each group. .
  • 0.2ml/10g was administered by continuous intragastric administration for 2 days, and 5% phenol red physiological saline 0.2ml/10g was intraperitoneally injected 30 minutes after the last administration. After 30 minutes, the mice were sacrificed and the trachea was separated, and a trachea from the thyroid cartilage to the tracheal branch was cut.
  • the test tube was placed in a test tube containing 3 ml of physiological saline, and 0.1 ml of a 15% sodium hydrogencarbonate solution was added.
  • the phenol red content was calculated from the phenol red standard curve. Standard curve: 0.1 ⁇ g/ml, 0.3 ⁇ g/ml, 0.5 ⁇ g/ml, 0.7 ⁇ g/ml, 1 ⁇ g/ml, 3 ⁇ g/ml, 5 ⁇ g/ml, and 10 ⁇ g/ml of phenol red standard solution were prepared. If the drug can increase the secretion function of the respiratory tract, it can increase the excretion of phenol red. Therefore, the difference in the content of phenol red can be compared.
  • naringin prepared according to daily dose of 120mg; non-soprenadine hydrochloride
  • the dosage of the composition (1) is 27.5mg of naringin and 30mg of fenofenadine hydrochloride; the composition of the composition (2) is 27.5mg of naringin, and the dosage of fentanyl hydrochloride
  • the composition of the composition (3) was prepared according to the daily dosage of naringin 275 mg and the non-sofofenine hydrochloride 30 mg; the composition (4) group was based on the daily dosage of naringin 275 mg, and fexofenadine hydrochloride.
  • Bronchoalveolar lavage and bronchoalveolar lavage (BALF) white blood cell differential count: After the AR measurement, guinea pigs were anesthetized with sodium pentobarbital 30 mg/kg, then the neck skin was cut and cut in the middle of the trachea. Small mouth, insert the tracheal tube. Bronchoalveolar lavage was performed with 5 mL of normal saline, and washed back and forth 3 times, and bronchoalveolar lavage fluid was collected. All bronchoalveolar lavage fluid 4 ° C
  • 2.6 lung tissue section Take the frozen part of the right lung tissue, routine fixation, dehydration, HE staining, observe the pathological changes of airway and lung tissue.
  • the number of coughs was significantly increased in the model group compared with the normal control group (P ⁇ 0.01).
  • each of the administration groups was able to reduce the number of coughs, which was statistically different from the model control group.
  • the number of coughs was significantly lower in the naringin and fexofenadine hydrochloride groups compared with the naringin alone or the fexofenadine hydrochloride alone group, and the difference was statistically significant (single dose alone) Group comparison, P ⁇ 0.05 or 0.01).
  • the above results demonstrate that the pharmaceutical composition has a good antitussive effect on ovalbumin-induced cough and is superior to the antitussive effect of each individual administration.
  • the total number of white blood cells, lymphocytes, neutrophils, and eosinophils were significantly higher in the model control group than in the normal control group (P ⁇ 0.01 compared with the normal control group); naringin, The administration of fexofenadine hydrochloride alone significantly reduced the total number of white blood cells, lymphocytes, neutrophils and eosinophils (P ⁇ 0.05 or 0.01 compared with the model group); each naringin and hydrochloric acid Solifenacin composition can significantly reduce the total number of white blood cells, lymphocytes, neutral particles
  • naringin and fexofenadine hydrochloride were significantly better than that of Otto group.
  • the naringin group and the fexofenadine hydrochloride group improved significantly.
  • naringin 40g Take naringin 40g, and fexofenadine 40g. First, mix fefofenadine hydrochloride with naringin, add 65g of starch and mix well, then add 5g of micro-silica gel, mix and put into 1000 capsules, then get capsule.
  • naringin 40g Take naringin 40g, and fexofenadine 40g.
  • the mixture of fexofenadine hydrochloride and naringin is first mixed, 120 g of starch is added, wet granulation, the granules are dried, 1 g of magnesium stearate is added, mixed, and pressed into 1000 tablets to obtain tablets.
  • naringin 40g Take naringin 40g, and fexofenadine 40g.
  • naringin 40g Take naringin 40g, and fexofenadine 40g. First, mix 48g of fexofenadine hydrochloride and lactose, then add naringin and starch 98g to mix, wet granulation, dry the granules, add 1g of magnesium stearate, mix and compress into 1000 pieces. tablet.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

一种用于止咳、化痰和平喘的柚皮苷药物组合物及其制剂，其特征在于：该药物组合物含柚皮苷27.5～275mg，和盐酸非索非那丁30～300mg。优选其中组合物中质量比为柚皮苷:盐酸非索非那丁＝1:1，其优选为每单位含柚皮苷40mg、盐酸非索非那丁40mg。该药物组合物可以治疗各种原因引起的咳嗽和痰多，以及治疗咳嗽变异性哮喘，药物组合物的药效优于柚皮苷或盐酸非索非那丁单独应用时的药效。该药物组合物可加入常规辅料，根据任何常规方法制备成止咳、化痰和平喘的药物。

Description

一种柚皮苷与盐酸非索非那丁药物组合物及其制剂 技术领域
本发明涉及一种用于止咳、化痰和平喘的柚皮苷药物组合物及其制剂。
背景技术
咳嗽、咯痰是呼吸系统疾病常见的两大症状，在病理上密切相关，一般咳嗽多夹痰，而痰多也常致咳嗽，长期不愈可能引发肺气肿、支气管扩张、肺心病等。咳嗽变异性哮喘，是指以慢性咳嗽为主要或唯一临床表现的一种特殊类型哮喘。
目前，药学药物中应用最广泛的止咳药物有磷酸可待因和氢溴酸右美沙芬等。
磷酸可待因是广泛用于止咳或感冒的中枢神经类化学药品，但近几年由于其严重不良反应一再被国家食品药品监督管理提高其管理级别。常见的不良反应有：心理变态或幻想；呼吸微弱、缓慢或不规则；心率或快或慢、异常。少见的不良反应：惊厥、耳鸣、震颤或不能自控的肌肉运动等；荨麻疹；疹痒、皮疹或脸肿等过敏反应；精神抑郁和肌肉强直等。长期应用可引起依赖性。常用量引起依赖性的倾向较其他吗啡类药为弱。典型的症状为：鸡皮疙瘩、食欲减退、腹泻、牙痛、恶心呕吐、流涕、寒颤、打喷嚏、打呵欠、睡眠障碍、胃痉挛、多汗、衰弱无力、心率增速、情绪激动或原因不明的发热。
氢溴酸右美沙芬也是常用的中枢神经类化学止咳药，消费者在药店可以买到。但随着其用量的增大，也出现了严重不良反应，特别是滥用情况，国外多次报道患者因过量服用粉状右美沙芬包装成的胶囊 造成死亡。美国食品药品监督管理局时刻关注右美沙芬的滥用情况，并发出不要滥用右美沙芬的警告。美国食品药品监督管理局表示，右美沙芬小剂量正确使用，可以安全有效地抑制感冒症状，但滥用可造成死亡和其他严重的不良反应，如脑损伤、癫痫发作、意识丧失和心跳不规则。
柚皮苷具有良好的止咳化痰平喘作用，且没有成瘾性，副作用极小。因此，开发疗效更好的柚皮苷复方制剂是开拓柚皮苷临床应用的很好途径。
发明内容
本发明提供了一种用于止咳、祛痰和平喘的柚皮苷药物组合物及其制剂。
该药物组合物由柚皮苷和盐酸非索非那丁组成，该组合物优选质量配比为：柚皮苷:盐酸非索非那丁＝1:1。日用量推荐柚皮苷含量为27.5～275mg、盐酸非索非那丁含量为30～300mg。其优选剂量为每一配剂(制剂)单位含柚皮苷40mg、盐酸非索非那丁40mg。
本发明两种药物组合物制成的药物具试验数据表明柚皮苷和盐酸非索非那丁按本发明的配比使用具有协同作用，复方疗效明显优于单组分的作用，更好的发挥了止咳、化痰和平喘的作用。采用本发明所述及的药物组合物能治疗咳嗽、咯痰和咳嗽变异性哮喘引起的喘息，且在服用时不会引起嗜睡、嗜睡、恶心、呕吐的副作用，该药物组合物可加入常规辅料，根据任何常规方法制备成止咳、祛痰和平喘的药物。
在研究中我们还对柚皮苷组合其他药物的作用进行了研究，结果表量柚皮苷分别与盐酸茶海拉明、盐酸茶苯海明马来酸氯苯那敏、氯 雷他定、地氯雷他定、盐酸氮卓斯汀、咪唑斯汀、盐酸依匹斯汀联合应用时，之间无协同。
具体实施方式
下面结合实施例对本发明做进一步的说明。
实施例1：对枸橼酸所致豚鼠咳嗽的抑制
1.材料
1.1实验动物合格Hartley豚鼠，体重250～300g，雌雄各半，由广东省医学实验动物中心提供。
1.2药物及试剂惠菲宁；柚皮苷按人日用量120mg配制；盐酸非索非那丁按人日用量60mg配制；组合物(1)组按人日用量柚皮苷27.5mg、盐酸非索非那丁30mg配制；组合物(2)组按人日用量柚皮苷27.5mg、盐酸非索非那丁300mg配制；组合物(3)组按人日用量柚皮苷275mg、盐酸非索非那丁30mg配制；组合物(4)组按人日用量柚皮苷275mg、盐酸非索非那丁300mg配制；组合物(5)组按人日用量柚皮苷120mg、盐酸非索非那丁120mg配制。
1.3仪器YLS-8A诱咳引喘仪(山东省医学科学设备站产品)。
2.方法
取合格Hartley豚鼠72只，体重250～300g，随机分为空白对照组、柚皮苷组、惠菲宁组、盐酸非索非那丁、组合物(1)～组合物(5)组，共9组，每组8只。各组豚鼠按0.5ml/100g体重灌胃给药，其中空白对照组给等体积生理盐水，灌胃给药1h后，开始接受枸橼酸喷雾7min，喷雾结束，观察并记录从喷雾开始时十分钟内咳嗽次数(典型咳嗽为咳嗽声音清脆响亮，常有前扑动作)。
3.结果
由表1可见，柚皮苷和盐酸非索非那丁药物单独给药，均具有显著镇咳作用(与空白组比较，P<0.05或0.01)；各柚皮苷和盐酸非索非那丁药物组合也均有良好的镇咳效果，且镇咳效果显著优于柚皮苷单独给药组或盐酸非索非那丁单独给药组，差异具有统计学意义(与单独给药组比较，P<0.05或0.01)。结果证明：该药物组合物具有良好的镇咳效果，且显著优于各自的单独给药组。
表1受试药物对枸橼酸诱导的咳嗽的抑制情况(n＝8)
Figure PCTCN2015088433-appb-000001
注：
1、与空白对照组比较，*P＜0.05，**P＜0.01；
2、与柚皮苷组比较，※P＜0.05,※※P＜0.01；
3、与盐酸非索非那丁组比较，□P＜0.05,□□P＜0.01。
实施例2：对小鼠酚红排泌实验的影响
1.材料
1.1实验动物昆明小鼠，雌雄各半，体重30～40g，由广东省医学实验动物中心提供。
1.2药物及试剂氨溴索；柚皮苷按人日用量120mg配制；盐酸非索非那丁按人日用量120mg配制；组合物(1)组按人日用量柚皮苷27.5mg、盐酸非索非那丁30mg配制；组合物(2)组按人日用量柚皮苷27.5mg、盐酸非索非那丁300mg配制；组合物(3)组按人日用量柚皮苷275mg、盐酸非索非那丁30mg配制；组合物(4)组按人日用量柚皮苷275mg、盐酸非索非那丁300mg配制；组合物(5)组按人日用量柚皮苷120mg、盐酸非索非那丁120mg配制。
1.3仪器日立3010紫外可见分光光度计。
2.方法
取昆明小鼠，雌雄各半，随机分为空白对照组、氨溴索组、柚皮苷组、盐酸非索非那丁、组合物(1)～组合物(5)组，每组10只。0.2ml/10g连续灌胃给药2d，末次给药后30min腹腔注射5％酚红生理盐水0.2ml/10g，30min后处死小鼠并分离气管，剪下自甲状软骨至气管分支处的一段气管，放入盛有3ml生理盐水的试管中，再加入0.1ml 15％的碳酸氢钠溶液.离心后取上清液，于546nln处测OD值。根据酚红标准曲线折算出酚红含量。标准曲线：分别配制0.1μg/ml、0.3μg/ml、0.5μg/ml、0.7μg/ml、lμg/ml、3μg/ml、5μg/ml、10μg/ml的酚红标准液。药物若能增加呼吸道的分泌功能，则能增加酚红的排泌量，所以测得酚红含量的高低，可以比较出药物排痰效果的差异。
3.结果
由表2可见，柚皮苷和盐酸非索非那丁药物单独给药，均能显著提高小鼠酚红排泌量(与空白组比较，P<0.05或0.01)的作用，具有显著祛痰作用；各柚皮苷和盐酸非索非那丁药物组合也均有良好的提高小鼠酚红排泌量效果，且提高小鼠酚红排泌量效果显著优于柚皮苷单独给药组或盐酸非索非那丁单独给药组，差异具有统计学意义(与单独给药组比较，P<0.05或0.01)。结果
证明：柚皮苷和盐酸非索非那丁药物组合有良好的祛痰效果，且祛痰效果优于柚皮苷单独给药组和盐酸非索非那丁单独给药组。
表2受试药物对小鼠酚红排泌实验的影响(n＝10)
Figure PCTCN2015088433-appb-000002
注：
1.与空白对照组比较，*P＜0.05，**P＜0.01；
2.与柚皮苷组比较，※P＜0.05,※※P＜0.01；
3.与盐酸非索非那丁组比较，□P＜0.05,□□P＜0.01。
实施例3：对卵清蛋白诱导所致过敏性咳嗽(咳嗽变异哮喘)的影响
1.材料
1.1实验动物：Hartley豚鼠，雄性，体重250～300g，SPF级，由广东省医学实验动物中心提供。
1.2药物及试剂环磷酰胺；卵清蛋白；辣椒素；乙酰甲胆碱；奥亭止咳露(复方磷酸可待因溶液)；柚皮苷按人日用量120mg配制；盐酸非索非那丁按人日用量120mg配制；组合物(1)组按人日用量柚皮苷27.5mg、盐酸非索非那丁30mg配制；组合物(2)组按人日用量柚皮苷27.5mg、盐酸非索非那丁300mg配制；组合物(3)组按人日用量柚皮苷275mg、盐酸非索非那丁30mg配制；组合物(4)组按人日用量柚皮苷275mg、盐酸非索非那丁300mg配制；组合物(5)组按人日用量柚皮苷120mg、盐酸非索非那丁120mg 配制。
1.3仪器设备：BUXCO咳嗽系统和全身体积描记系统(美国BUXCO公司)。
2.方法
2.1分组：雄性Hartley豚鼠，体重250～300g，随机分为正常对照组、模型对照组、奥亭组、柚皮苷组、盐酸非索非那丁组、组合物(1)～组合物(5)组，每组10只。
2.2造模：除正常对照组外，其余各组豚鼠按如下方法致敏：即第1d以30mg/kg剂量腹腔注射环磷酰胺；第3d腹腔注射含卵蛋白2mg和氢氧化铝100mg的混悬液1mL；3周后再次注入含卵蛋0.01mg和氢氧化铝100mg的混悬液1mL，正常组豚鼠腹腔注射生理盐水1mL；3周后所有造模动物雾化吸入1％卵蛋白溶液90s激发，正常对照组雾化吸入生理盐水90s。
2.3给药：激发后24h，各组按照表1所示剂量给药，连续给药7天。豚鼠咳嗽次数的测定：末次给药1h后，将豚鼠置于Buxco咳嗽记录仪中，采用50μmol/L的辣椒素引咳，总量1ml，记录10min(含雾化时间)内的咳嗽次数。
2.4豚鼠气道反应性(AR)的测定：咳嗽测定后24h，用Buxco全身体积描记系统中检测豚鼠的增强呼气间歇(Enhanced Pause,Penh)。测定乙酰甲胆碱(MeCh)雾化激发后Penh的变化，MeCh激发浓度由低到高，依次为100mg/L,200mg/L,400mg/L,800mg/L,1600mg/L，记录各浓度级MeCh激发下的Penh平均值。将每个MeCh激发浓度下的Penh值转换为与生理盐水(NS)激发时Penh值的百分比，以Penh％表示，作为AR的评价指标。
2.5支气管肺泡灌洗及支气管肺泡灌洗液(BALF)白细胞分类计数：AR测定结束后，豚鼠采用戊巴比妥钠30mg/kg进行麻醉，然后剪开颈部皮肤，并于气管正中处剪开小口，插入气管套管。以生理盐水5mL行支气管肺泡灌洗，来回冲洗3次，收集支气管肺泡灌洗液。全部的支气管肺泡灌洗液4℃
离心1500rpm×10min，上清液－80℃保存备用。
2.6肺组织切片：取右肺部分组织行冰冻切片，常规固定，脱水，行HE染色，观察气道及肺组织病理学改变。
3.结果
3.1咳嗽次数
由表3可见，模型组与正常对照组比较，咳嗽次数显著增多(P<0.01)。给药后，各个给药组均能降低咳嗽次数，与模型对照组比较，在统计学上有差异。各柚皮苷和盐酸非索非那丁组合物组与柚皮苷单独给药组或盐酸非索非那丁独给药组比较，咳嗽次数显著降低，差异具有统计学意义(与单独给药组比较，P<0.05或0.01)。以上结果证明，药物组合物对于卵清蛋白诱导的咳嗽有良好的镇咳效果，且均优于各自单独给药的镇咳效果。
表3受试药物对豚鼠辣椒素引咳的抑制(n＝10)
Figure PCTCN2015088433-appb-000003
注：
1.与正常对照组比较，##P＜0.01；
2.与模型对照组比较，*P＜0.05，**P＜0.01；
3.与柚皮苷组比较，※P＜0.05,※※P＜0.01；
4.与盐酸非索非那丁组比较，□P＜0.05,□□P＜0.01。
3.2气道反应性
由表4可见，与正常对照组比较，模型组气道反应性明显提高(与正常对照组比较,P<0.01)；给药后，各组药物均能降低气道反应性；其中，各柚皮苷和盐酸非索非那丁组合物，降低乙酰甲胆碱(MeCh)所致气道高反应的作用优于柚皮苷单独给药组或盐酸非索非那丁单独给药组(与单独给药组比较，P<0.05或0.01)。结果表明，柚皮苷和盐酸非索非那丁药物组合物对卵清蛋白诱导的咳嗽变异性哮喘有显著的平喘作用，且均优于各自的单独给药组。
表4受试药物对豚鼠气道反应性的影响(n＝10)
Figure PCTCN2015088433-appb-000004
注：1.与正常对照组比较，#P＜0.01，##P＜0.01；
2.与模型对照组比较，*P＜0.05，**P＜0.01；
3.与柚皮苷组比较，※P＜0.05,※※P＜0.01；
4.与盐酸非索非那丁组比较，□P＜0.05,□□P＜0.01。
3.3肺泡灌洗液白细胞分类计数结果
由表5可见，模型对照组与正常对照组比较，白细胞总数、淋巴细胞、中性粒细胞和嗜酸性粒细胞总数均明显升高(与正常对照组比较,P<0.01)；柚皮苷、盐酸非索非那丁单独给药，也能显著降低白细胞总数、淋巴细胞、中性粒细胞和嗜酸性粒细胞总数(与模型组比较，P<0.05或0.01)；各柚皮苷和盐酸非索非那丁组合物，均能显著降低白细胞总数、淋巴细胞、中性粒
细胞和嗜酸性粒细胞总数(与模型组比较，P<0.05或0.01)，且与柚皮苷单独给药组或盐酸非索非那丁单独给药组相比，其降低白细胞总数、中性粒细胞数、淋巴细胞数和嗜酸性粒细胞数的作用更显著(与单独给药组比较，P<0.05或0.01)。结果证明药物组合物在抑制炎症细胞方面均优于各自的单独给药组。
表5受试药物对豚鼠肺泡灌洗液白细胞分类计数的结果(n＝10)
Figure PCTCN2015088433-appb-000005
注：
1.与正常对照组比较，#P＜0.01，##P＜0.01；
2.与模型对照组比较，*P＜0.05，**P＜0.01；
3.与柚皮苷组比较，※P＜0.05,※※P＜0.01；
4.与盐酸非索非那丁组比较，□P＜0.05,□□P＜0.01。
3.4肺组织切片结果
给药后，从炎症细胞浸润程度，肺泡壁水肿和充血程度，肺泡腔结构和支气管腔完整程度等方面综合评价，柚皮苷与盐酸非索非那丁药物各组合物组明显比奥亭组、柚皮苷组、盐酸非索非那丁组改善明显。
实施例4：
取柚皮苷40g，盐酸非索非那丁40g。先将盐酸非索非那丁与柚皮苷混匀，再加淀粉65g混匀，再加入微粉硅胶5g，混匀，装入1000粒胶囊中，即得胶囊剂。
实施例5：
取柚皮苷40g，盐酸非索非那丁40g，再加乳糖65g混匀，再加入微粉硅胶5g，混匀，装入1000粒胶囊中，即得胶囊剂。
实施例6：
取柚皮苷40g，盐酸非索非那丁40g。先将盐酸非索非那丁与柚皮苷混匀，再加入淀粉120克，湿法制粒，颗粒干燥，加入硬脂酸镁1g，混匀，压成1000片，即得片剂。
实施例7：
取柚皮苷40g，盐酸非索非那丁40g。先将柚皮苷、盐酸非索非那丁混匀，加糊精30g、淀粉88克混匀，加入微粉硅胶2g，混匀，装入1000粒胶囊中，即得胶囊剂。
实施例8：
取柚皮苷40g，盐酸非索非那丁40g。先将盐酸非索非那丁加乳糖48g混匀，再加入柚皮苷、淀粉98克混匀，湿法制粒，颗粒干燥，加入硬脂酸镁1g，混匀，压成1000片，即得片剂。

Claims (6)

  1. 一种柚皮苷药物组合物，其特征在于：该种药物组合物由柚皮苷27.5～275mg及盐酸非索非那丁30～300mg组成。
  2. 根据权利要求1所述的药物组合物，其特征在于：柚皮苷和盐酸非索非那丁的质量配比为1:1。
  3. 根据权利要求1和2所述的药物组合物，其特征在于：该种药物组合物由柚皮苷40mg和盐酸非索非那丁40mg组成。
  4. 根据权利要求1至3所述药物组合物所制成的临床可接受的制剂。
  5. 根据权利要求4所述的制剂，其特征在于：所述制剂为片剂、胶囊剂、水剂或气雾剂。
  6. 根据权利要求5所述的制剂，其特征在于：所述的制剂辅料为淀粉、乳糖、甘露醇、磷酸氢钙、羧甲基淀粉或其盐及基团取代物、糊精、壳聚糖、聚乙烯吡咯烷酮、纤维素及其衍生物或聚乙二醇。
PCT/CN2015/088433 2014-09-18 2015-08-28 一种柚皮苷与盐酸非索非那丁药物组合物及其制剂 WO2016041438A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201410479695.6A CN104188998A (zh) 2014-09-18 2014-09-18 一种柚皮苷与盐酸非索非那丁药物组合物及其制剂
CN201410479695.6 2014-09-18

Publications (1)

Publication Number Publication Date
WO2016041438A1 true WO2016041438A1 (zh) 2016-03-24

Family

ID=52074475

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2015/088433 WO2016041438A1 (zh) 2014-09-18 2015-08-28 一种柚皮苷与盐酸非索非那丁药物组合物及其制剂

Country Status (2)

Country Link
CN (1) CN104188998A (zh)
WO (1) WO2016041438A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104188998A (zh) * 2014-09-18 2014-12-10 中山大学 一种柚皮苷与盐酸非索非那丁药物组合物及其制剂
CN107573393A (zh) * 2017-10-23 2018-01-12 梅州金柚康健康科技有限公司 一种低糖基化普鲁宁的制备及其在抗炎平喘药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1267221A (zh) * 1997-08-14 2000-09-20 赫斯特·马里昂·罗素公司 增强Fexofenadine及其衍生物之生物利用度的方法
CN104188998A (zh) * 2014-09-18 2014-12-10 中山大学 一种柚皮苷与盐酸非索非那丁药物组合物及其制剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1217669C (zh) * 2003-01-21 2005-09-07 中山大学 柚皮苷用于制备治疗咳嗽的药物
CN101543476B (zh) * 2009-05-05 2011-01-26 中山大学 一种柚皮苷固体分散体及其制备方法和应用
GB0921803D0 (en) * 2009-12-14 2010-01-27 Biocopea Ltd Drug composition and its use in therapy
CN103622905A (zh) * 2013-12-17 2014-03-12 中山大学 一种矫味柚皮苷口服溶液及其制备方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1267221A (zh) * 1997-08-14 2000-09-20 赫斯特·马里昂·罗素公司 增强Fexofenadine及其衍生物之生物利用度的方法
CN104188998A (zh) * 2014-09-18 2014-12-10 中山大学 一种柚皮苷与盐酸非索非那丁药物组合物及其制剂

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MING THAU SHEU ET AL.: "A quantitative structure-activity relationship for the modulation effects of flavonoids on p-glycoprotein-mediated transport Chem.", PHARM.BULL., vol. 58, no. 9, 30 September 2010 (2010-09-30), pages 1190 *

Also Published As

Publication number Publication date
CN104188998A (zh) 2014-12-10

Similar Documents

Publication Publication Date Title
KR101480595B1 (ko) 기관지염 치료를 위하여 제약조성물 및 이를 만드는 제조방법
CN101549060B (zh) 一种含有麻黄的治疗支气管炎的药物及其制备方法
CN104127667B (zh) 一种治疗慢性咽炎的药物组合物及其制备方法
CN102805746A (zh) 一种作用于呼吸系统疾病的复方化学药及其制备工艺与应用
MX2014002125A (es) Tratamiento de sintomas asociados a gastroparesia femenina.
WO2016041438A1 (zh) 一种柚皮苷与盐酸非索非那丁药物组合物及其制剂
WO2016041439A1 (zh) 一种柚皮苷与盐酸左西替利嗪药物组合物及其制剂
US9867789B2 (en) Non-steroidal anti-inflammatory drugs for cough
JPH0680577A (ja) 鎮咳剤
CN109200051A (zh) 石杉碱甲及其类似物作为治疗炎症性疾病药物的用途
JP2002363072A (ja) 鎮咳用組成物
CN104257803A (zh) 一种治疗打呼的药物组合物及其制备方法和用途
CN105232991B (zh) 一种治疗胃黏膜损伤的药物组合物
CN109106714B (zh) 止咳、化痰和平喘的药物组合物及其制剂
CN117018132B (zh) 一种用于治疗咳嗽变异性哮喘的中药
US20080033010A1 (en) Combination therapy of erdosteine and beta-2 agonists for treating respiratory pathologies characterized by non reversible or partially reversible airway obstruction
CN112245435B (zh) 一种用于解救钩吻中毒的组合物及其应用
CN103961654B (zh) 一种白葡萄球菌片及其制备方法
CN107595868B (zh) 去半乳糖替告皂甙在制备治疗支气管炎药物中的应用
CN114984001B (zh) 格隆溴铵在制备用于预防恶心和呕吐症状的药物中的用途
RU2611383C2 (ru) Комбинированный препарат для устранения симптомов и лечения острых респираторных вирусных инфекций и гриппа
JP2009007332A (ja) アゼラスチン類とエフェドリン類を含有する医薬組成物
Truter Evidence Based Pharmacy Practice: cough
CN106215080A (zh) 一种含有盐酸丙卡特罗的治疗小儿支气管哮喘的药物组合物及其制备方法
CN105769908B (zh) 一种化痰止咳的药物及其制备方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15841766

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15841766

Country of ref document: EP

Kind code of ref document: A1